PTC Therapeutics Inc Asset Resilience Ratio
PTC Therapeutics Inc asset resilience ratio. PTC Therapeutics Inc (PTCT) has an Asset Resilience Ratio of 36.89% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of PTC Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of PTC Therapeutics Inc (2004–2025)
Asset resilience ratio of PTC Therapeutics Inc from 2004 to 2025. This chart shows how PTC Therapeutics Inc's Asset Resilience Ratio has changed over time. See PTCT free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down PTC Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PTCT asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.06 Billion | 36.89% |
| Total Liquid Assets | $1.06 Billion | 36.89% |
Asset Resilience Insights
- Very High Liquidity: PTC Therapeutics Inc maintains exceptional liquid asset reserves at 36.89% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
PTC Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare PTC Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
PTC Therapeutics Inc Asset Resilience Ratio by Year (2004–2025)
PTC Therapeutics Inc asset resilience ratio by year from 2004 to 2025. The table below shows the annual Asset Resilience Ratio data for PTC Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 33.00% | $960.72 Million | $2.91 Billion | +11.89pp |
| 2024-12-31 | 21.11% | $359.99 Million | $1.71 Billion | +6.20pp |
| 2023-12-31 | 14.91% | $282.74 Million | $1.90 Billion | +7.24pp |
| 2022-12-31 | 7.67% | $130.87 Million | $1.71 Billion | -22.44pp |
| 2021-12-31 | 30.12% | $583.66 Million | $1.94 Billion | -10.41pp |
| 2020-12-31 | 40.52% | $894.84 Million | $2.21 Billion | +15.98pp |
| 2019-12-31 | 24.54% | $398.54 Million | $1.62 Billion | +19.35pp |
| 2018-12-31 | 5.19% | $58.09 Million | $1.12 Billion | -15.10pp |
| 2017-12-31 | 20.29% | $79.45 Million | $391.65 Million | -44.07pp |
| 2016-12-31 | 64.36% | $173.34 Million | $269.35 Million | -11.97pp |
| 2015-12-31 | 76.32% | $280.90 Million | $368.04 Million | -3.35pp |
| 2014-12-31 | 79.68% | $265.49 Million | $333.22 Million | -3.97pp |
| 2013-12-31 | 83.64% | $127.05 Million | $151.90 Million | +22.52pp |
| 2005-12-31 | 61.12% | $26.88 Million | $43.97 Million | -6.14pp |
| 2004-12-31 | 67.26% | $26.21 Million | $38.97 Million | -- |
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervo… Read more